Pancreatic Cell News Volume 3.35 | Sep 4 2012

The Apoptosis Inhibitor ARC Alleviates the ER Stress Response to Promote β-Cell Survival
Scientists demonstrated that apoptosis repressor with caspase recruitment domain (ARC) is a previously unrecognized inhibitor of apoptosis in β-cells and that its protective effects are mediated through suppression of the endoplasmic reticulum (ER) stress response pathway. [Diabetes] Abstract

DIABETES

The Role of Raf-1 Kinase Inhibitor Protein in the Regulation of Pancreatic Beta Cell Proliferation in Mice
Scientists investigated the involvement of raf-1 kinase inhibitor protein 1 in the control of beta cell mass and function. [Diabetologia] Abstract

Quantitative Determination of Apoptosis of Pancreatic β-Cells in a Murine Model of Type 1 Diabetes Mellitus
Researchers investigated the incidence of β-cell apoptosis in streptozotocin-treated mice and nonobese diabetic mice with ^99mTc-annexin A5. [J Nucl Med] Abstract

β-Arrestin 1 Mediated Recruitment of c-Src Underlies the Proliferative Action of Glucagon-Like Peptide-1 in Pancreatic β INS832/13 Cells
Investigators showed that glucagon-like peptide-1 increased c-Src phosphorylation in INS832/13 cells, an effect inhibited by siRNA-mediated β-arrestin 1 knockdown. [Mol Cell Endocrinol] Abstract

FTY720 Preserved Islet β-Cell Mass by Inhibiting Apoptosis and Increasing Survival of β-Cells in Db/Db Mice
Researchers investigated the effect of FTY720 on apoptosis in β-cells in db/db mice treated with FTY720 at 16 weeks. [Diabetes Metab Res Rev] Abstract

PANCREATIC CANCER

Glutamate-Ammonia Ligase and Reduction of G0 Population in PANC-1 Cells
Investigators discovered that glutamate-ammonia ligase overexpression shifted the major population of PANC-1 cells from the G0/G1 phase to G2/M phase. [J Cell Biochem] Abstract

Identification of Novel Predictive Markers for the Prognosis of Pancreatic Ductal Adenocarcinoma
To identify novel molecular markers that could predict the prognosis of pancreatic ductal adenocarcinoma, scientists collected 114 pancreatic ductal adenocarcinomas and 99 peritumoral tissues. [Hum Pathol] Abstract

The Novel ATR Inhibitor VE-821 Increases Sensitivity of Pancreatic Cancer Cells to Radiation and Chemotherapy
Researchers investigated the sensitization potential of the first highly selective and potent ATR inhibitor, VE-821, in vitro. [Cancer Biol Ther] Abstract

Development of a Unique Mouse Model for Pancreatic Cancer Lymphatic Metastasis
Investigators established a pancreatic cancer cell and mouse model with high lymphatic metastasis potential for in-depth study of the underlying mechanisms. The BxPC-3-LN subline was established through serial passages in nude mice via footpad injections. [Int J Oncol] Abstract

REVIEWS

GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus
This review discusses various glucagon-like peptide-1 (GLP-1) receptor agonists that have been developed to provide prolonged in vivo actions. [Nat Rev Endocrinol] Abstract

Pancreatic Cancer Action Network-AACR Grants Program Offers More than $4 Million for Pancreatic Cancer Research
The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network announced the opening of the 2013 research grants program. [American Association for Cancer Research]
Press Release

Rexahn Pharmaceuticals Announces Positive Top-Line Phase IIa Data for Archexin in Patients with Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals announced top-line results from a phase II clinical study of Archexin®, its clinical-stage oncology drug candidate. [Rexahn Pharmaceuticals, Inc.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

National Health Service (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 6^th International Conference on Advanced Technologies & Treatments for Diabetes
February 27-March 2, 2012
Paris, France

Visit our events page to see a complete list of events in the pancreatic cell community.

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Clinical Investigator – Biomedical Research Program (Weill Cornell Medical College)

Postdoctoral Position – Type 2 Diabetic Human Induced Pluripotent Stem Modeling (University of Lille Nord de France)

Postdoctoral Position – Cancer Therapeutics (Massachusetts General Hospital)

Postdoctoral Position – Dysfunction in Diabetes (University of Oxford)

Postdoctoral Position – Beta Cell Biology and Translational Research (University of California)

Postdoctoral Position – Epigenetics and Diabetes (Weill Cornell Medical College in Qatar)

Postdoctoral Fellow (University of South Alabama Mitchell Cancer Institute)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.